< Terug naar vorige pagina

Publicatie

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer

Tijdschriftbijdrage - Tijdschriftartikel

Most high-grade serous ovarian carcinoma (HGSOC) patients benefit from first-line platinum-based chemotherapy, but progressively develop resistance during subsequent lines. Re-activating BRCA1 or MDR1 mutations can underlie platinum resistance in end-stage patients. However, little is known about resistance mechanisms occurring after a single line of platinum, when patients still qualify for other treatments.
Tijdschrift: EUROPEAN JOURNAL OF CANCER
ISSN: 0959-8049
Volume: 53
Pagina's: 51 - 64
Jaar van publicatie:2015
BOF-keylabel:ja
IOF-keylabel:ja
BOF-publication weight:3
CSS-citation score:2
Auteurs:International
Authors from:Government, Higher Education
Toegankelijkheid:Closed